• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

Five Tech Stocks to Lap Up at the Bottom

Tech Letter

Tech has led the way to the downside as the macro picture sours in the short term.

Valuations have come down from the nosebleed levels and now is the time to pick and choose where to allocate capital for the next leg up in tech.

Avoiding growth tech is something that should be stapled to your bedpost, loss-making companies won’t be able to compete with more established revenue models.

You don’t want to catch a falling knife, but at the same time, diligently prepare yourself to buy the best discounts of the year.

Here are the names of five of the best stocks to slip into your portfolio in no particular order when we find a bottom.

Remember, tech ALWAYS comes back.

Apple

Steve Job’s creation is weathering the gale-force storm quite well. Apple has been on a tear reconfirming its smooth pivot to a software service tilted tech company. The timing is perfect as China has enhanced its smartphone technology by leaps and bounds.

Even though China cannot produce the top-notch quality phones that Apple can, they have caught up to the point local Chinese are reasonably content with its functionality.

That hasn’t stopped Apple from vigorously growing revenue in greater China 20% YOY during a feverishly testy political climate that has their supply chain in Beijing’s crosshairs.

The pivot is picking up steam and Apple’s revenue will morph into a software company with software and services eventually contributing 25% to total revenue.

They aren’t just an iPhone company anymore. Apple has led the charge with stock buybacks and will gobble up a total of $200 billion in shares by the end of 2021. Get into this stock while you can, as entry points are few and far between.

Oh, and their 5G phone is selling like hotcakes. Some one billion need to be replaced to bring consumers into the new high speed 5G world.

Amazon (AMZN)

This is the best company in America, hands down, and commands 5% of total American retail sales or 49% of American e-commerce sales. The pandemic has vastly accelerated the growth of their business.

It became the second company to eclipse a market capitalization of over $1 trillion. Its Amazon Web Services (AWS) cloud business pioneered the cloud industry and had an almost 10-year head start to craft it into its cash cow. Amazon has branched off into many other businesses since then, oozing innovation, and is a one-stop wrecking ball.

The newest direction is the smart home where they seek to place every single smart product around the Amazon Echo, the smart speaker sitting nicely inside your house. A smart doorbell was the first step along with recently investing in a pre-fab house start-up aimed at building smart homes.

Microsoft (MSFT)

The optics in 2021 look utterly different from when Bill Gates was roaming around the corridors in the Redmond, Washington headquarter -- and that is a good thing.

Current CEO Satya Nadella has turned this former legacy company into the 2nd largest cloud competitor to Amazon and then some.

Microsoft Azure is rapidly catching up to Amazon in the cloud space because of the Amazon effect working in reverse. Companies don’t want to store proprietary data to Amazon’s server farm when they could possibly destroy them down the road. Microsoft is mainly a software company and gained the trust of many big companies, especially retailers.

Microsoft is also on the vanguard of the gaming industry and deals like the $86 billion purchase of Activision (ATVI) mean that it will be difficult for another company to loosen MSFTs stranglehold at the top of the gaming ladder.

Alphabet (GOOGL)

Alphabet and Facebook boast a strong duopoly of ad technology. Alphabet generated 80% of its revenue from Google's advertising services in 2020. Google's non-advertising businesses (including subscriptions and hardware) accounted for 12%, while another 7% came from Google Cloud.

Alphabet's total revenue rose 13% in 2020, even as the pandemic throttled the growth of Google's advertising business in the first half of the year. The growth of Google Cloud throughout the year also cushioned that blow.

Google's advertising business recovered in the second half of the year, and Alphabet's operating margin expanded from 21% in 2019 to 23% in 2020. Its diluted earnings per share (EPS) also grew 19%.

In the first nine months of 2021, Alphabet's revenue rose 45% year over year as Google's advertising and cloud business grew in tandem.

Its array of different businesses like LinkedIn, YouTube, and Google Maps means this revenue pipeline is as fertile as can be.

Google’s robust balance sheet will protect itself from any downtrend in business that they might ever suffer.

Tesla (TSLA)

The influential EV leader has really surged ahead of the competition during the pandemic.

Demand for its product is off the charts as they delivered 184,800 Model 3 and Model Y cars in the first quarter, beating expectations and setting a record for Tesla.

However, the company also said it produced none of its higher-end Model S sedans or Model X SUVs for the period ending March. It delivered 2,020 older Model S sedans and Model X SUVs from inventory.

Supply chain issues are likely to remain a challenge for Tesla this year as many EV makers are having a hard time sourcing semiconductor chips.

Tesla is now aiming to produce 2,000 Model S and X vehicles per week later this year.

The company said Monday it expects more than 50% vehicle delivery growth in 2021 overall, which implies minimum deliveries of around 750,000 vehicles this year.

This stock is a must-buy when tech reverses.

 

 

tech bottom

 

tech bottom

 

tech bottom

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-21 14:02:342022-01-28 23:41:59Five Tech Stocks to Lap Up at the Bottom
Mad Hedge Fund Trader

Trade Alert - (TLT) January 21, 2022 - BUY

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-21 11:59:302022-01-21 11:59:30Trade Alert - (TLT) January 21, 2022 - BUY
Mad Hedge Fund Trader

Trade Alert - (SPY) January 21, 2022 - BUY

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-21 10:54:262022-01-21 10:54:26Trade Alert - (SPY) January 21, 2022 - BUY
Mad Hedge Fund Trader

January 20, 2022

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
January 20, 2022
Fiat Lux

Featured Trade:

(A NO-BRAINER DIVIDEND CONTENDER UP FOR GRABS)
(AMGN), (ABBV), (GILD), (REGN), (JNJ)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-20 17:02:332022-01-20 17:35:43January 20, 2022
Mad Hedge Fund Trader

No-Brainer Dividend Contender Up For Grabs

Biotech Letter

To say that biotechnology stocks haven’t been performing well as of late is an understatement.

Over the past 12 months, the SPDR S&P Biotech Exchange Traded Fund (XBI) has recorded an over 30% loss and is anticipated to reach its 52-week low soon.

Investors have been pulling back from biotechnology stocks for several reasons like threats of drug pricing reforms in the US, the ever-increasing interest rates, and of course, the lure of rapid-growth assets such as cryptocurrencies.

Nevertheless, all is still not lost for the biotechnology sector.

The industry, in its entirety, continues to move forward with unprecedented innovations.

These groundbreaking discoveries, in turn, offer a myriad of untapped, top-value markets that will bode well for long-term investors.

This means that savvy investors would do well to make the most of this broad selloff in a highly promising segment.

One way to determine quality names in this volatile sector is to choose dividend-paying stocks.

After all, dividends are excellent sources of passive income. Apart from that, these can easily boost your portfolio if you plan to reinvest your money.

Basically, regardless of your investment strategy, choosing dividend-paying businesses can be really helpful in reaching your goals.

Among the names in the biotech industry, one that looks promising these days is Amgen (AMGN).

While Amgen’s dividend yield isn’t as high as the likes of AbbVie (ABBV) and Gilead Sciences (GILD), this pioneering biotechnology company is still a promising investment.

Recently, Amgen reported another dividend increase of 10.2%, indicating a rise from $1.76 to reach $1.94 per quarter, with the subsequent dividend expected to be payable by March 2022. 

This results in an annual dividend of $7.76 and a respectable dividend yield of 3.41%.

More impressively, Amgen has been paying out dividends since 2011 and boosted its dividend not only annually but with an 11.97% in CAGR over the past 5 years.

Given the company’s history and growth trajectory, Amgen’s earnings growth rate annually in the next 5 years is estimated to be 6%, while its yearly dividend hike rate is projected at 7%.

At first glance, it’s easy to dismiss Amgen’s current standing.

In the third quarter of 2021, the company’s total revenue only reached $6.7 billion, indicating a measly 4% rise year-over-year.

A potential reason for this underwhelming growth is the pending patent cliff for some of its key products and the threat of biosimilars taking over Amgen’s target markets.

For example, cancer medication Neulasta reported a 25% decline in its sales year-over-year to contribute only $415 million in the third quarter.

Needless to say, this kind of disheartening top-line growth is partly responsible for the stock’s sluggish performance in the market lately.

However, other products in the company’s portfolio have reported much better performances than Neulasta.

There’s osteoporosis treatment Prolia, which rose by 15% year-over-year to contribute $803 million in the same period.

Even cholesterol drug Repatha showed off a 33% growth to record $272 million, while arthritis medication Otezla’s sales climbed by 13% to rake in $609 million.

On top of these, Amgen has also succeeded in developing new products that can easily provide additional revenue streams.

One of the most promising recently approved products is advanced non-small-cell lung cancer (NSCLC) treatment Lumakras, which received the US FDA green light last year.

Although there are many approved drugs for this condition, Lumakaras is the first and only treatment that targets specific mutations among non-squamous NSCLC patients.

This translates to 13% of patients suffering from that particular condition.

This is a massive market for Amgen.

Back in 2019, lung cancer was identified as the leading cause of cancer deaths in the United States.

At that time, the total was 139,603 individuals, which made up 23% of all the deaths attributed to the condition. Among the lung cancer deaths, 84% were identified to be of the NSCLC category.

So, if you put everything in perspective, the 13% patient population that Amgen exclusively holds equates to a big opportunity.

In addition, the European Union already approved Lumakras as well. This opens up yet another massive market for the treatment.

In the third quarter of 2021, Lumakras only delivered $36 million in sales. With the recent approvals and broadening of markets, this drug’s revenue is projected to rise quickly.

Aside from these products, Amgen has been working on expanding its pipeline. To date, the company has over 20 ongoing Phase 3 clinical trials.

Moreover, Amgen has decided to take a page out of the books of biosimilar developers.

As the company witnessed its own products get pummeled by biosimilars in the market, Amgen has opted to cannibalize sales of a wide range of treatments that lost their patent exclusivities.

This strategy has already delivered rewards, with the company reporting at least $2 billion in annual sales from its biosimilars in 2021.

For 2022, Amgen has three more biosimilars under development and is looking into poaching the likes of Regeneron’s (REGN) Eylea and Johnson & Johnson’s (JNJ) Stelara as well.

Despite the pandemic, Amgen has managed to extend its dividend growth streak to reach 11 consecutive years. This makes this biotechnology company an impressive Dividend Contender.

Overall, I consider this company a solid buy and an excellent long-term investment. It’s not simply an undervalued pick for value investors but also an outstanding choice for dividend investors.

 

dividend

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-20 17:00:222022-01-27 13:57:46No-Brainer Dividend Contender Up For Grabs
Mad Hedge Fund Trader

January 20, 2022

Bitcoin Letter

 

Mad Hedge Bitcoin Letter
January 20, 2022
Fiat Lux

Featured Trade:

(PAY FOR YOUR HOUSE IN BITCOIN)
(BTC), (MILO)

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-20 16:04:392022-01-20 17:39:05January 20, 2022
Mad Hedge Fund Trader

Pay for Your House in Bitcoin

Bitcoin Letter

Crypto continues to benefit from higher adoption rates and although it doesn’t filter down to the price of Bitcoin (BTC) immediately, it bodes well for the long term.

I am even surprised myself with how Bitcoin has transformed from a speculative asset into something more sustainable.

There have been several events that have also hastened the adoption of crypto and one of the transformational events was the advent of Bitcoin ETFs that are accessible for the average investor.

This was never the case before as people were highly confused about how to participate.

The next monumental shift on the verge of sweeping up another avalanche of new capital is the integration of crypto into the American property market.

Most Americans’ net wealth is tied to their home and, United Wholesale Mortgage – the second-largest US mortgage lender – announced a move to crypto payments last August.

However, despite widespread popular sentiment for the initiative from potential customers, the company gave up on the idea shortly afterward.

The regulatory uncertainty alongside market volatility was cited as the two main headwinds.

Nonetheless, the trend is moving in favor again as the first bitcoin mortgage offering was announced on Tuesday: confirming that while the regulators lack drafting a framework.

A real estate fintech company Milo announced the launch of the world’s first crypto mortgage: enabling borrowers to leverage their bitcoin holdings to buy real estate in the United States.

CEO of Milo Josip Rupera said that customers could obtain bitcoin-backed loans by using their bitcoin holdings as collateral for purchasing a property.

Customarily, first, customers needed to sell their crypto balance for a down payment by converting it into fiat currency.

However, Milo now allows US citizens and foreigners to qualify for a US-based mortgage based on their BTC holdings.

This is another indicator of BTC being massively valued as a form of alternative payment.

Milo offers crypto loans and has promised to expand their debt offerings to BTC holders.

Milo’s clients will be able to pledge their bitcoin to purchase property and finally qualify for a low-interest rate 30-year crypto mortgage.”

The company clarified earlier that ‘no dollar down payments’ would be required to finance the mortgage: making the procedure faster and more efficient. However, an obvious question pops up again: what about the sharp movements in the price of bitcoin acting as collateral?

Similar to other crypto loans, the crypto-mortgage would be launched with a margin-call component.

Milo would then underwrite the customer, evaluate the property, validate other aspects of creditworthiness, and ultimately facilitate a successful transaction.

If, however, the crypto drops in value, the borrower would be subject to the deficit amount if the assets are underwater.

Milo would allow the borrower to pay in fiat currency or pledge more crypto to adjust the margin account to its minimum maintenance margin.

Attaching itself to the coattails of the most stable asset in America could act as the panacea of crypto’s evils.

Expert bang on saying crypto is a poor store of value, well, if it's used to underpin an American house, then that argument goes out the window.

Making a path from Bitcoin to real estate debt is genius.

Milo has been planning this business since last year. The goal was to allow crypto holders to bypass the complex hassle with traditional banks and lenders, which barely consider crypto as an asset class. Instead, the company aimed to offer an alternative route to buy real estate.

Milo estimates that the crypto mortgage market could be worth tens of billions of dollars soon.

The marriage of mortgage lending and crypto would be the elixir to finally kill that volatility that many don’t like about this asset.

There’s nothing more stable about a physical home and the U.S. property market underpinning crypto is essentially the holy grail of the crypto industry into how this asset can really mainstream into every part of the U.S. economy.

Until then, accepting heightened volatility is part and parcel of crypto, and crypto settling in the $40,000 range shows that crazy fluctuations aren’t as common as they used to be.

To check out more about a crypto-backed mortgage or if you are thinking about taking out a crypto-backed mortgage, go to Milo’s homepage by clicking here.

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2022/01/crypto-house.png 572 928 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-20 16:02:542022-01-25 17:00:26Pay for Your House in Bitcoin
Mad Hedge Fund Trader

Quote of the Day - January 20, 2022

Bitcoin Letter

“Bitcoin is a swarm of cyber hornets serving the goddess of wisdom, feeding on the fire of truth, exponentially growing ever smarter, faster, and stronger behind a wall of encrypted energy.” – Said CEO of MicroStrategy Michael J. Saylor

https://www.madhedgefundtrader.com/wp-content/uploads/2022/01/michael-saylor-1.png 490 342 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-20 16:00:302022-01-20 17:37:12Quote of the Day - January 20, 2022
Mad Hedge Fund Trader

Trade Alert - (AAPL) January 20, 2022 - BUY

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-20 13:09:002022-01-20 13:09:00Trade Alert - (AAPL) January 20, 2022 - BUY
Mad Hedge Fund Trader

January 20, 2022

Diary, Newsletter, Summary

Global Market Comments
January 20, 2022
Fiat Lux

Featured Trades:

(HOW THE MAD HEDGE MARKET TIMING ALGORITHM TRIPLED MY PERFORMANCE)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2022-01-20 10:04:582022-01-20 12:29:22January 20, 2022
Page 6 of 14«‹45678›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top